Rock Springs Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Buy |
150,450
+24,950
| +20% | +$3.31M | 1.17% | 27 |
|
|
2025
Q4 | $17.8M | Buy |
125,500
+35,750
| +40% | +$5.18M | 0.91% | 37 |
|
|
2025
Q3 | $12.6M | Buy |
89,750
+950
| +1% | +$129K | 0.74% | 47 |
|
|
2025
Q2 | $11.2M | Sell |
88,800
-190,200
| -68% | -$21.8M | 0.7% | 51 |
|
|
2025
Q1 | $30.9M | Sell |
279,000
-441,500
| -61% | -$55.9M | 1.77% | 19 |
|
|
2024
Q4 | $98.3M | Sell |
720,500
-218,500
| -23% | -$27M | 3.74% | 4 |
|
|
2024
Q3 | $108M | Sell |
939,000
-1,000
| -0.1% | -$137K | 3.52% | 6 |
|
|
2024
Q2 | $129M | Sell |
940,000
-114,900
| -11% | -$15.8M | 3.9% | 4 |
|
|
2024
Q1 | $145M | Sell |
1,054,900
-141,100
| -12% | -$19.3M | 3.69% | 3 |
|
|
2023
Q4 | $158M | Sell |
1,196,000
-40,000
| -3% | -$4.6M | 3.88% | 4 |
|
|
2023
Q3 | $139M | Sell |
1,236,000
-43,500
| -3% | -$4.58M | 3.72% | 4 |
|
|
2023
Q2 | $121M | Buy |
1,279,500
+69,400
| +6% | +$6.78M | 2.87% | 8 |
|
|
2023
Q1 | $122M | Buy |
1,210,100
+87,600
| +8% | +$9.12M | 2.92% | 8 |
|
|
2022
Q4 | $134M | Hold |
1,122,500
| – | – | 3.23% | 5 |
|
|
2022
Q3 | $119M | Hold |
1,122,500
| – | – | 3.08% | 6 |
|
|
2022
Q2 | $109M | Buy |
1,122,500
+17,500
| +2% | +$1.62M | 3.18% | 5 |
|
|
2022
Q1 | $104M | Hold |
1,105,000
| – | – | 2.61% | 7 |
|
|
2021
Q4 | $94.1M | Buy |
1,105,000
+53,500
| +5% | +$4.92M | 2.17% | 10 |
|
|
2021
Q3 | $101M | Buy |
1,051,500
+36,500
| +4% | +$3.45M | 2.12% | 10 |
|
|
2021
Q2 | $98.8M | Hold |
1,015,000
| – | – | 1.95% | 9 |
|
|
2021
Q1 | $98.7M | Sell |
1,015,000
-560,000
| -36% | -$58.7M | 2.15% | 7 |
|
|
2020
Q4 | $151M | Buy |
1,575,000
+109,500
| +7% | +$10.6M | 3.2% | 1 |
|
|
2020
Q3 | $141M | Buy |
1,465,500
+99,000
| +7% | +$11.5M | 3.58% | 2 |
|
|
2020
Q2 | $167M | Buy |
1,366,500
+17,000
| +1% | +$1.88M | 4.57% | 1 |
|
|
2020
Q1 | $117M | Buy |
1,349,500
+71,500
| +6% | +$7M | 4.83% | 1 |
|
|
2019
Q4 | $137M | Buy |
1,278,000
+45,500
| +4% | +$4.76M | 4.34% | 2 |
|
|
2019
Q3 | $111M | Buy |
1,232,500
+209,500
| +20% | +$19.6M | 4.43% | 2 |
|
|
2019
Q2 | $86.4M | Buy |
1,023,000
+178,500
| +21% | +$14.7M | 3.12% | 5 |
|
|
2019
Q1 | $74.4M | Buy |
844,500
+55,900
| +7% | +$4.67M | 2.87% | 6 |
|
|
2018
Q4 | $56.3M | Buy |
788,600
+143,600
| +22% | +$13.8M | 2.66% | 7 |
|
|
2018
Q3 | $79.3M | Buy |
645,000
+14,600
| +2% | +$1.66M | 2.87% | 4 |
|
|
2018
Q2 | $61.9M | Buy |
630,400
+24,200
| +4% | +$2.17M | 2.38% | 4 |
|
|
2018
Q1 | $50.3M | Buy |
606,200
+120,200
| +25% | +$10.2M | 2.14% | 5 |
|
|
2017
Q4 | $37.7M | Buy |
486,000
+46,000
| +10% | +$3.14M | 1.71% | 14 |
|
|
2017
Q3 | $27M | Buy |
440,000
+21,000
| +5% | +$1.11M | 1.24% | 21 |
|
|
2017
Q2 | $19.3M | Buy |
419,000
+9,000
| +2% | +$437K | 0.97% | 32 |
|
|
2017
Q1 | $17.8M | Hold |
410,000
| – | – | 1.02% | 33 |
|
|
2016
Q4 | $15.9M | Hold |
410,000
| – | – | 1.06% | 29 |
|
|
2016
Q3 | $20.8M | Buy |
410,000
+500
| +0.1% | +$24.9K | 1.3% | 26 |
|
|
2016
Q2 | $18.6M | Buy |
409,500
+5,000
| +1% | +$230K | 1.38% | 21 |
|
|
2016
Q1 | $16M | Buy |
404,500
+27,000
| +7% | +$1.07M | 1.34% | 24 |
|
|
2015
Q4 | $21.4M | Buy |
377,500
+3,500
| +0.9% | +$178K | 1.62% | 19 |
|
|
2015
Q3 | $14.9M | Sell |
374,000
-2,000
| -0.5% | -$96.7K | 1.21% | 22 |
|
|
2015
Q2 | $18M | Buy |
376,000
+1,000
| +0.3% | +$42.4K | 1.31% | 23 |
|
|
2015
Q1 | $14.9M | Buy |
375,000
+15,000
| +4% | +$537K | 1.39% | 26 |
|
|
2014
Q4 | $8.04M | Buy |
360,000
+45,000
| +14% | +$853K | 0.94% | 38 |
|
|
2014
Q3 | $4.94M | Buy |
315,000
+5,000
| +2% | +$74.7K | 0.76% | 41 |
|
|
2014
Q2 | $4.6M | Buy |
310,000
+10,000
| +3% | +$141K | 0.82% | 46 |
|
|
2014
Q1 | $4.83M | Buy |
+300,000
| New | +$5.13M | 1.11% | 28 |
|
Other funds holding NBIX
VPM
VCM
Rock Springs Capital Management's NBIX Position: Q1 2026 in Review
Rock Springs Capital Management increased its Neurocrine Biosciences (NBIX) stake by 20% in Q1 2026, buying an estimated $3.31M and bringing the position to 150,450 shares worth $19.8M. The position accounts for 1.17% of the portfolio, ranked #27.
Rock Springs Capital Management first reported a position in NBIX in Q1 2014 and has held it in 49 quarters since. The position peaked at $167M in Q2 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Rock Springs Capital Management held 150,450 shares of Neurocrine Biosciences worth $19.8M as of Q1 2026.
- Rock Springs Capital Management bought 24,950 Neurocrine Biosciences shares in Q1 2026, an estimated $3.31M.
- Neurocrine Biosciences made up 1.17% of Rock Springs Capital Management's portfolio in Q1 2026, its #27 holding.
- Rock Springs Capital Management first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 49 quarters since.
- Rock Springs Capital Management's Neurocrine Biosciences position peaked at $167M in Q2 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.